Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation.

ABSTRACT: Abiraterone acetate and Enzalutamide are novel anti-androgens that are key treatments to improve both progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. In this study, we aimed to determine whether combinations of AR inhibitors with radiation are additive or synergistic, and investigated the underlying mechanisms governing this. This study also aimed to compare and investigate a biological rationale for the selection of Abiraterone versus Enzalutamide in combination with radiotherapy as currently selection is based on consideration of side effect profiles and clinical experience. We report that AR suppression with Enzalutamide produces a synergistic effect only in AR-sensitive prostate models. In contrast, Abiraterone displays s

SUBMITTER: Wright TC 

PROVIDER: S-EPMC8335570 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature